Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals
Article first published online: 15 APR 2010
Copyright © 2010 John Wiley & Sons, Ltd.
Rapid Communications in Mass Spectrometry
Volume 24, Issue 10, pages 1481–1489, 30 May 2010
How to Cite
Salehpour, M., Ekblom, J., Sabetsky, V., Håkansson, K. and Possnert, G. (2010), Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals. Rapid Commun. Mass Spectrom., 24: 1481–1489. doi: 10.1002/rcm.4544
- Issue published online: 28 APR 2010
- Article first published online: 15 APR 2010
- Manuscript Revised: 11 MAR 2010
- Manuscript Accepted: 11 MAR 2010
- Manuscript Received: 26 JAN 2010
Accelerator Mass Spectrometry (AMS) is an ultra-sensitive analytical method which has been instrumental in developing microdosing as a strategic tool in early drug development. Considerable data is available for AMS microdosing using typical pharmaceutical drugs with a molecular weight of a few hundred Daltons. The so-called biopharmaceuticals such as proteins offer interesting possibilities as drug candidates; however, experimental data for protein microdosing and AMS is scarce. The analysis of proteins in conjunction with early drug development and microdosing is overviewed and three case studies are presented on the topic. In the first case study AMS experimental data is presented, for the measured concentration of orally administered recombinant insulin in the blood stream of laboratory rabbits. Case study 2 concerns minimum sample size requirements. AMS samples normally require about 1 mg of carbon (10 µL of blood) which makes AMS analysis unsuitable in some applications due to the limited availability of samples such as human biopsies or DNA from specific cells. Experimental results are presented where the sample size requirements have been reduced by about two orders of magnitude. The third case study concerns low concentration studies. It is generally accepted that protein pharmaceuticals may be potentially more hazardous than smaller molecules because of immunological reactions. Therefore, future first-in-man microdosing studies might require even lower exposure concentrations than is feasible today, in order to increase the safety margin. This issue is discussed based on the current available analytical capabilities. Copyright © 2010 John Wiley & Sons, Ltd.